See more : Capital Power Corporation (CPXWF) Income Statement Analysis – Financial Results
Complete financial analysis of Phathom Pharmaceuticals, Inc. (PHAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phathom Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangxi LiuYao Group Co., Ltd (603368.SS) Income Statement Analysis – Financial Results
- LATAM Airlines Group S.A. (LTMAQ) Income Statement Analysis – Financial Results
- Sino-i Technology Limited (SNOIF) Income Statement Analysis – Financial Results
- Ferrexpo plc (FEEXY) Income Statement Analysis – Financial Results
- Shree Vasu Logistics Limited (SVLL.NS) Income Statement Analysis – Financial Results
Phathom Pharmaceuticals, Inc. (PHAT)
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 682.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 167.00K | 620.00K | 521.00K | 300.00K | 8.00K | 0.00 |
| Gross Profit | 515.00K | -620.00K | -521.00K | -300.00K | -8.00K | 0.00 |
| Gross Profit Ratio | 75.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.90M | 71.44M | 72.34M | 98.15M | 99.27M | 20.00K |
| General & Administrative | 0.00 | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.93M | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Other Expenses | 0.00 | -110.00K | -2.06M | -8.00K | -49.56M | -50.00K |
| Operating Expenses | 167.83M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Cost & Expenses | 167.99M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Interest Income | 7.88M | 2.13M | 41.00K | 1.09M | 1.09M | 0.00 |
| Interest Expense | 41.97M | 27.31M | 6.79M | 4.58M | 4.18M | 13.00K |
| Depreciation & Amortization | 575.00K | 620.00K | 521.00K | 300.00K | 8.00K | 1.23M |
| EBITDA | -159.05M | -171.82M | -134.56M | -124.19M | -250.95M | -50.00K |
| EBITDA Ratio | -23,320.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -167.31M | -172.44M | -135.08M | -125.67M | -106.22M | -1.23M |
| Operating Income Ratio | -24,532.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -34.28M | -25.28M | -8.80M | -3.40M | -148.92M | -63.00K |
| Income Before Tax | -201.59M | -197.72M | -143.88M | -129.07M | -255.13M | -1.29M |
| Income Before Tax Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 25.28M | 4.21M | 4.25M | -45.39M | 13.00K |
| Net Income | -201.59M | -223.01M | -148.09M | -133.32M | -209.74M | -1.29M |
| Net Income Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| EPS Diluted | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Weighted Avg Shares Out | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
| Weighted Avg Shares Out (Dil) | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly...
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate...
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET...
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate...
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its...
Source: https://incomestatements.info
Category: Stock Reports